|
|
|
|
|||||
|
|
|
West Pharmaceutical Services, Inc. (NYSE:WST) is included among the 13 Best Consistent Dividend Stocks to Buy Now.
On October 29, TD Cowen analyst Brendan Smith initiated coverage of West Pharmaceutical Services, Inc. (NYSE:WST) with a Buy rating and a price target of $350, as reported by The Fly. He noted that West is well-positioned at the intersection of several major industry trends, including injectable biologics, GLP-1 treatments, and growing regulatory requirements. These factors have allowed the company to move from being a traditional supplier of standard drug delivery components to offering high-value products with stronger margins. The analyst added that this ongoing shift toward higher-value offerings is expected to support sustained revenue and margin growth over the long term.
On October 23, West Pharmaceutical Services, Inc. (NYSE:WST) reported its third-quarter 2025 results, with net sales of $804.6 million, an increase of 7.7% year over year, and organic growth of 5%. The growth was broad-based across both Proprietary Products and Contract Manufacturing segments, led by double-digit expansion in high-value product components, continued progress in GLP-1 products, and increased Annex 1 conversions supported by an improving demand environment.
From a cash flow standpoint, West Pharmaceutical Services, Inc. (NYSE:WST) maintained solid financial performance. Operating cash flow rose 8.7% from the prior year to $503.7 million, while free cash flow climbed 53.7% to $293.9 million, highlighting its ability to generate stable cash and support dividends.
West Pharmaceutical Services, Inc. (NYSE:WST) designs, manufactures, and markets products that support the development and delivery of pharmaceuticals, biologics, vaccines, and consumer healthcare solutions.
While we acknowledge the potential of WST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 13 Most Undervalued Dividend Stocks to Buy According to Wall Street Analysts and 15 Dividend Growth Stocks with the Highest Growth Rates
Disclosure: None.
| Nov-03 | |
| Oct-31 | |
| Oct-31 | |
| Oct-31 | |
| Oct-30 | |
| Oct-27 | |
| Oct-24 | |
| Oct-24 | |
| Oct-24 | |
| Oct-24 | |
| Oct-23 | |
| Oct-23 | |
| Oct-23 | |
| Oct-23 | |
| Oct-23 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite